Ibritumomab Tiuxetan and Sargramostim Intravenous
Determining the interaction of Ibritumomab Tiuxetan and Sargramostim Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ibritumomab tiuxetan during or too soon after completion of a course of sargramostim treatment may alter the effects of either medication. Sargramostim should generally not be given within 2 weeks before or 2 weeks after treatment with ibritumomab tiuxetan. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with ibritumomab have not been established. Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ibritumomab therapeutic regimen and for 2 weeks following completion of the regimen.
MANAGEMENT: Until further data are available, it may be appropriate to avoid using hematopoietic growth factors within 2 weeks before or 2 weeks after the ibritumomab regimen.
- "Product Information. In-111 Zevalin (ibritumomab)." IDEC Pharmaceuticals Corporation, San Diego, CA.
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab
Generic Name: sargramostim
Brand name: Leukine
Synonyms: Sargramostim
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ibritumomab Tiuxetan-Sargramostim Powder for Injection
- Ibritumomab Tiuxetan-Sargramostim Solution for Injection
- Ibritumomab Tiuxetan-Sarilumab
- Ibritumomab Tiuxetan-Sarilumab Prefilled Pens
- Ibritumomab Tiuxetan-Sarilumab Prefilled Syringes
- Ibritumomab Tiuxetan-Sarilumab Subcutaneous
- Sargramostim Intravenous-Ibrutinib
- Sargramostim Intravenous-Ibrutinib Capsules
- Sargramostim Intravenous-Ibrutinib Tablets
- Sargramostim Intravenous-Ibu
- Sargramostim Intravenous-IBU Tablets
- Sargramostim Intravenous-Ibu-2